5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 5, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 3, Active not recruiting 1, Terminated 1 |
Follow LGX818: new trials by email Literature Review of LGX818 trials Research Report on LGX818
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-10-30 |
| Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors Encorafenib - BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC | Phase 1 | Completed | Pierre Fabre Medicament | 3 | 2021-09-27 | 2024-06-24 |
| Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer Binimetinib, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma | Phase 1 | Terminated | University of California, San Francisco | 2 | 2020-08-31 | 2023-01-09 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Binimetinib, Encorafenib - Advanced BRAF Mutant Cancers | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-14 | 2024-10-21 |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2014-12-01 | 2017-10-09 |
| Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. LEE011, LGX818 - Locally Advanced Metastatic BRAF Mutant Melanoma | Phase 1 / Phase 2 | Terminated | Array BioPharma | 28 | 2013-07-01 | 2016-09-13 |
| A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors LGX818, MEK162, LEE011 - Solid Tumors Harboring a BRAF V600 Mutation | Phase 1 / Phase 2 | Completed | Pfizer | 189 | 2012-05-28 | 2024-03-13 |
| A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma LGX818 - Melanoma and Metastatic Colorectal Cancer | Phase 1 | Completed | Pfizer | 107 | 2011-09-05 | 2024-10-28 |
Colorectal Neoplasms (5) · Melanoma (3) · Colonic Neoplasms (2) · Neoplasm Metastasis (2) · Rectal Neoplasms (2) · Disease Progression (1)
Array BioPharma (2) · Pfizer (2) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · Pierre Fabre Medicament (1) · University of California, San Francisco (1)
United States (8) · Australia (4) · Canada (3) · France (3) · Spain (3) · Belgium (2) · Italy (2) · Netherlands (2) · Singapore (2) · Switzerland (2) · China (1) · Israel (1) · Japan (1) · Norway (1)
Array BioPharma (1) · Chloe E Atreya, MD, PhD (1) · Li Zhang, MD (1) · Rona Yaegar, MD (1) · Salvador Alonso Martinez (1) · Van K Morris (1)
PMID 32669376, PMID 35385748, PMID 36811382, PMID 40578933, PMID 40611889, PMID 42101296
UM1CA186688 (1)